Table 2.
Disposition of patients with CLBP enrolled in 4 randomized, placebo-controlled trials of duloxetine treatment14–17
| Disposition category | Placebo | Duloxetine 60 mg |
|---|---|---|
| Entered, n | 653 | 642 |
| Completed, n (%) | 535 (81.9) | 520 (81.0) |
| Discontinued, n (%) | ||
| Adverse event | 31 (4.7) | 70 (10.9) |
| Patient decision | 39 (6.0) | 21 (3.3) |
| Protocol violation | 11 (1.7) | 12 (1.9) |
| Lack of efficacy | 22 (3.4) | 8 (1.2) |
| Physician decision | 4 (0.6) | 4 (0.6) |
| Lost to follow-up | 4 (0.6) | 4 (0.6) |
| Entry criteria not met | 2 (0.3) | 2 (0.3) |
| Sponsor decision | 1 (0.2) | 0 (0.0) |
| Others | 4 (0.6) | 1 (0.2) |
Abbreviation: CLBP, chronic low back pain.